Annexin A2: A tissue plasminogen activator amplifier for thrombolytic stroke therapy Academic Article uri icon


MeSH Major

  • Annexin A2
  • Brain Ischemia
  • Stroke
  • Thrombolytic Therapy
  • Tissue Plasminogen Activator


  • Hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and the short treatment time window comprise major challenges for thrombolytic therapy. Improving tissue plasminogen activator therapy has become one of the highest priorities in the stroke field. Recent efforts have been aimed at identifying new strategies that might enhance the thrombolytic efficacy of tissue plasminogen activator at the same time as reducing its associated complications related to hemorrhage and neurotoxicity. We believe that the combination of low-dose tissue plasminogen activator with recombinant annexin A2 (a tissue plasminogen activator and plasminogen coreceptor) might constitute a promising approach. Our pilot study using a focal embolic stroke model in rats supports this hypothesis.

publication date

  • October 2010



  • Academic Article



  • eng

PubMed Central ID

  • PMC2994255

Digital Object Identifier (DOI)

  • 10.1161/STROKEAHA.110.596106

PubMed ID

  • 20876506

Additional Document Info

start page

  • S54

end page

  • 8


  • 41


  • 10 SUPPL. 1